IHMA

Rising Demand for Secure Packaging Solutions and Enhanced Aesthetic Appeal Propels Market to US$ 432.1M by 2034 | Future Market Insights, Inc.

Retrieved on: 
Monday, March 11, 2024
Holo, Growth, Sample, Indian stock exchange, Printing, Research, Electronics, Investment, Safety, IHMA, Cosmetics, Marketing, Security printing

NEWARK, Del., March 11, 2024 /PRNewswire/ -- The market for holographic blister foil is rapidly growing and is predicted to reach a valuation of US$ 272.9 million in 2024. By 2034, the market is expected to surge to US$ 432.1 million and expand at a CAGR of 4.7% over the forecast period. One of the main drivers of this growth is the increasing demand for secure packaging solutions due to rising concerns regarding counterfeit products across various industries. The pharmaceutical sector's reliance on blister packaging is a significant factor fueling the demand for holographic blister foils to ensure product safety and authenticity.

Key Points: 
  • One of the main drivers of this growth is the increasing demand for secure packaging solutions due to rising concerns regarding counterfeit products across various industries.
  • The pharmaceutical sector's reliance on blister packaging is a significant factor fueling the demand for holographic blister foils to ensure product safety and authenticity.
  • Stringent regulatory standards mandating secure packaging solutions have bolstered the market demand, ensuring industry compliance.
  • "The demand for anti-counterfeiting solutions in pharmaceutical and electronic industries boosts the growth prospects of the holographic blister foil market.

Rising Demand for Secure Packaging Solutions and Enhanced Aesthetic Appeal Propels Market to US$ 432.1M by 2034 | Future Market Insights, Inc.

Retrieved on: 
Monday, March 11, 2024
Holo, Growth, Sample, Indian stock exchange, Printing, Research, Electronics, Investment, Safety, IHMA, Cosmetics, Marketing, Security printing

NEWARK, Del., March 11, 2024 /PRNewswire/ -- The market for holographic blister foil is rapidly growing and is predicted to reach a valuation of US$ 272.9 million in 2024. By 2034, the market is expected to surge to US$ 432.1 million and expand at a CAGR of 4.7% over the forecast period. One of the main drivers of this growth is the increasing demand for secure packaging solutions due to rising concerns regarding counterfeit products across various industries. The pharmaceutical sector's reliance on blister packaging is a significant factor fueling the demand for holographic blister foils to ensure product safety and authenticity.

Key Points: 
  • One of the main drivers of this growth is the increasing demand for secure packaging solutions due to rising concerns regarding counterfeit products across various industries.
  • The pharmaceutical sector's reliance on blister packaging is a significant factor fueling the demand for holographic blister foils to ensure product safety and authenticity.
  • Stringent regulatory standards mandating secure packaging solutions have bolstered the market demand, ensuring industry compliance.
  • "The demand for anti-counterfeiting solutions in pharmaceutical and electronic industries boosts the growth prospects of the holographic blister foil market.

Venatorx Pharmaceuticals Highlights Two Recent Publications Indicating Rising Metallo-Beta-Lactamases for Carbapenem-Resistant Enterobacterales in US

Retrieved on: 
Monday, August 14, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, MBL, Enterobacterales, IDSA, JMI, MBL deficiency, Medication, SBL, Genetically modified bacteria, Hospital, Publication, IHMA, Johns Hopkins University, Patient, Viral, Klebsiella, CRE, Epidemiology, Vaccine, Pharmaceutical industry, Asia-Pacific Telecommunity band plan

When looking deeper at the specific contribution from carbapenemase families, metallo-beta-lactamases (MBLs) were the most frequently identified carbapenem resistance mechanism.

Key Points: 
  • When looking deeper at the specific contribution from carbapenemase families, metallo-beta-lactamases (MBLs) were the most frequently identified carbapenem resistance mechanism.
  • In the U.S. and Canada, MBLs were found in 15.5% of all CRE isolates in 2018-2019, or approximately 1 out of every 7 CRE isolates.
  • This represents a 300% increase from the 2012-17 period when only 5% of CRE isolates expressed MBLs in the US and Canada.
  • [4] of Johns Hopkins University analyzed consecutive CRE clinical isolates collected from unique patients at 3 US hospitals from 2016-2021.

Bugworks Research Inc. to Present Eight Posters at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023, in Copenhagen, Denmark

Retrieved on: 
Monday, April 17, 2023
Infection, University of Texas Medical Branch, University, Survival, Research, University of Liverpool, Congress, WRAIR, ECCMID, IHMA, European, Walter Reed Army Institute of Research, Mouse, Pharmaceutical industry

and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ -- Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set to present its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark.

Key Points: 
  • and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ -- Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set to present its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark.
  • Bugworks Research is at the forefront of developing novel antibiotics to combat the growing threat of antimicrobial resistance.
  • The ECCMID conference is a leading global forum for infectious diseases and clinical microbiology.
  • Attendees are invited to visit the Bugworks Research booth to learn more about the company's innovative approach to fighting antibiotic resistance.

Bugworks Research Inc. to Present Eight Posters at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023, in Copenhagen, Denmark

Retrieved on: 
Monday, April 17, 2023
Infection, University of Texas Medical Branch, University, Survival, Research, University of Liverpool, Congress, WRAIR, ECCMID, IHMA, European, Walter Reed Army Institute of Research, Mouse, Pharmaceutical industry

and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ -- Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set to present its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark.

Key Points: 
  • and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ -- Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set to present its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark.
  • Bugworks Research is at the forefront of developing novel antibiotics to combat the growing threat of antimicrobial resistance.
  • The ECCMID conference is a leading global forum for infectious diseases and clinical microbiology.
  • Attendees are invited to visit the Bugworks Research booth to learn more about the company's innovative approach to fighting antibiotic resistance.

NFL Sports Betting Revenue Skyrocketed 40% in 2022

Retrieved on: 
Tuesday, February 7, 2023
Ekeler, Apple Music, Wilson, Alcohol, Seattle Seahawks, Internet, LA, Denver, Marketing, Kansas City Chiefs, History of the Buffalo Bills, Denver Broncos, Socio-analysis, Athlete, Food, Los Angeles Chargers, Business intelligence, Intelligence, NFL, FanDuel, IMHA, MGM Resorts International, Health care, Buffalo Bills, Philadelphia Eagles, Daily fantasy sports, Juju, Partnership, Wine & Spirits, K, History of the Los Angeles Rams, Sport, Gambling, Bally, Sports betting, Social media, IHMA, Insurance

STAMFORD, Conn., Feb. 7, 2023 /PRNewswire/ -- SponsorUnited, the leading global sports and entertainment intelligence platform tracking 1.1 million sponsorships and endorsements across 250,000 brands and properties, today released its NFL 2022 Marketing Partnerships Report, which revealed team sponsorship revenues increased 14% year-over-year, setting a new league record.

Key Points: 
  • Key findings from the report include:
    Sports Betting has become a key revenue stream for the NFL, increasing 40% across teams.
  • Sports Betting deals have quadrupled in the last four years (2019-2022), while gambling companies accelerated their ad spend last year.
  • More than 25 NFL teams now have at least one Sports Betting or Daily Fantasy Sport sponsor.
  • Sponsorship revenue totaled $2.05B across the 32 NFL teams in the 2022-2023 season–a new league record, and a 14% increase year-over-year.

Introducing a New Antifungal Surveillance Program: Analysis of Resistance to Antifungals (ARIA) and Expanded Mycology Services at IHMA

Retrieved on: 
Thursday, October 7, 2021
Research, Infectious Diseases, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Antifungal, Hospital, Mycology, Program, Microbiology, International, Analysis, Monthey, Industry, Medical Mycology, ARIA, IHMA, Vaccine, Pharmaceutical industry

International Health Management Associates (IHMA) has initiated a new antifungal resistance surveillance program, Analysis of Resistance to Antifungals (ARIA) to further the development of new antifungal agents and monitor the development of antifungal resistance.

Key Points: 
  • International Health Management Associates (IHMA) has initiated a new antifungal resistance surveillance program, Analysis of Resistance to Antifungals (ARIA) to further the development of new antifungal agents and monitor the development of antifungal resistance.
  • IHMA offers an option for biopharmaceutical companies to add new antifungal agents to the program.
  • The first presentation of ARIA data - Analysis of Resistance In Antifungals (ARIA) - Global Surveillance of Candida spp.
  • Isolates, Including C. auris, in 2019 - will be made at the upcoming 10th Trends in Medical Mycology (TIMM-10), 8-11 October 2021, Aberdeen, Scotland.

IHMA Opens Microbiology Reference Laboratory in Shanghai, China to Further Support Global Anti-Infective Product Discovery and Development

Retrieved on: 
Wednesday, September 22, 2021
Health, Infectious Diseases, General Health, Research, Science, Pharmaceutical, Biotechnology, Industry, Microbiology, IHMA, Antibiotics

IHMA has opened a microbiology reference laboratory in Shanghai, China in February of 2021.

Key Points: 
  • IHMA has opened a microbiology reference laboratory in Shanghai, China in February of 2021.
  • This facility will join IHMA locations in the USA, Switzerland and India to allow the company to provide more robust global support for anti-infective product discovery and development.
  • As the leading global microbiology service provider to the biopharmaceutical industry, IHMA utilizes its extensive laboratory and industry expertise to support efficient and effective anti-infective product development.
  • IHMA is a premier provider of reference laboratory services to support anti-infective product discovery and development as well as the development of diagnostic devices that detect bacterial resistance to antimicrobial agents and new technologies as they emerge.